Cerecor (CERC) Takes Upward Bounce; Seres Therapeutics (MCRB) Chaotic Plummet On Disappointing CDI Drug Study


Cerecor Inc. (Nasdaq:CERC) stock soared to reach the $4.25 mark in intraday trading Friday, currently changing hands at $3.60, up $0.95 (or +35.85%) with 526,826 shares traded so far, representing a large increase in activity compared with its average volume (3m) of 17,076

There appears to be no relevant recent information from the clinical-stage biopharmaceutical company that may explain the stock’s rally

Cerecor, which develops drugs to treat patients with neurological and psychiatric disorders, has 8.65M Shares Outstanding and CERC stock 52-week range is between $1.94 and $5.19 per share



Shares of Seres Therapeutics, Inc. (Nasdaq:MCRB) plummeted more than 77% to touch a new 52-week low of $8.05 in early trade Friday after the company said that a mid-stage study evaluating its lead development drug SER-109 in patients with multiply recurrent Clostridium difficile infection (CDI) has failed to meet the primary endpoint of reducing the risks associated with the infection

MCRB stock is trading at $10.62, down $25.15 (or -70.31%) and 32.02M shares of the microbiome therapeutics platform company changed hands so far

Seres Therapeutics, which focuses on the development of biological drugs designed to restore health by repairing the function of a dysbiotic microbiome, has 39.52M Shares Outstanding and MCRB stock one-year range is now from $8.05 to $52.00 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/